Documents to download

According to the NHS, medical cannabis, also known as medicinal cannabis, is “a broad term for any sort of cannabis-based medicine used to relieve symptoms”. The cannabis plant contains more than a hundred different chemical compounds called cannabinoids, some of which are the active ingredients in prescription medicines. The most well-known cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD).

Under the Misuse of Drugs Act 1971, cannabis (as well as most cannabinoids) is a controlled drug. Prior to September 2018, cannabis-based medicinal products could only be accessed through the granting of an individual licence. Following a review by the Chief Medical Officer and the Advisory Council on the Misuse of Drugs, the Home Office announced that from 1 November 2018 cannabis-based medicinal products would be rescheduled under the relevant regulations, meaning they could be prescribed by doctors on the Specialist Register of the General Medical Council.

Cannabis use for medicinal purposes is allowed in several countries and territories across the world. These include the Netherlands, Canada, France, Germany and some US states. In the Netherlands, for example, cannabis for medicinal purposes is available with a physician’s prescription and can be prescribed by all doctors.

In December 2018, the House of Commons Health and Social Care Committee launched an inquiry into issues around medicinal cannabis. The committee stated that while the rescheduling of cannabis for medicinal purposes had been “widely welcomed”, there had been a “failure” to communicate what this would mean “in practice”. In September 2019, the Government responded to the recommendations set out in the committee’s report. These included providing clearer information on availability and building the evidence base.

New National Institute for Health and Care Excellence (NICE) guidelines were published in November 2019 on the prescribing of cannabis-based products. The guidance recommends specific cannabis-based products in the treatment of intractable nausea and vomiting and for spasticity in Multiple Sclerosis (MS), but not for the treatment of pain. The guidelines did not recommend these products for severe treatment-resistant epilepsy, however NICE made research recommendations in this area.

Documents to download

Related posts

  • Net zero transformation: Industry and Regulators Committee report

    In March 2022, the House of Lords Industry and Regulators Committee published a report on net zero transformation, examining the government’s policy to achieve net zero emissions by 2050. The committee argued that current plans “lack the necessary level of policy detail” and proposed a range of recommendations. This article summarises the report, the government’s and Ofgem’s responses, as well as other developments concerning the UK’s net zero strategy.

    Net zero transformation: Industry and Regulators Committee report
  • Mortality rates among men and women: impact of austerity

    Improvements in life expectancy have slowed in the UK since the early 2010s. A recent study argued there have been over 300,000 excess deaths during this period, when comparing trends in life expectancy with those from before 2011. The authors of the study argue this is a result of austerity policies pursued by the government. The subject is due to be debated in the House of Lords on 12 January 2023.

    Mortality rates among men and women: impact of austerity
  • Cost of living: The healthcare ecosystem

    This article explores how the rising cost of living has affected the UK healthcare ecosystem. Rising energy prices and food insecurity can lead to an increasingly ill population, while staff shortages and high hospital bills add pressure to the health system. In November 2022, the UK government announced an £8bn spending increase for health and adult social care, but some organisations have said it is not enough.

    Cost of living: The healthcare ecosystem